Esperion Therapeutics (NASDAQ:ESPR) Has Just Been Downgraded by Citigroup to a Neutral Rating

January 23, 2018 - By Vivian Currie

  Esperion Therapeutics (NASDAQ:ESPR) Has Just Been Downgraded by Citigroup to a Neutral Rating

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.

Schwab Charles Investment Management Incorporated invested in 91,843 shares. First Tru Advisors Lp stated it has 9,205 shares. United Kingdom-based Legal & General Group Inc Pcl has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Manufacturers Life The holds 13,095 shares or 0% of its portfolio. Victory Cap Mgmt holds 0% or 282 shares. Ubs Asset Mgmt Americas Inc accumulated 39,898 shares. Nj State Employees Deferred Compensation Plan owns 0.12% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 13,125 shares. Citigroup reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Pinnacle Associates Limited reported 0.66% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Blackrock stated it has 1.52M shares. Iguana Healthcare Ltd Liability Co accumulated 150,000 shares. Dimensional Fund Advsrs L P invested in 90,750 shares or 0% of the stock. Switzerland-based Gam Ag has invested 0.48% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). First Mercantile Tru Communication, a Tennessee-based fund reported 2,714 shares. Metropolitan Life Ins Communication Ny reported 0% stake.

Esperion Therapeutics (NASDAQ:ESPR) Receives a Downgrade

The stock rating of Esperion Therapeutics (NASDAQ:ESPR) was downgraded by research professionals at Citigroup from a the old Buy rating to a more updated Neutral in a research report sent to investors and clients on Monday, 22 January. The brokerage firm currently has a $96 target price on shares, suggesting a possible upside of 23.19 %.

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.

Schwab Charles Investment Management Incorporated invested in 91,843 shares. First Tru Advisors Lp stated it has 9,205 shares. United Kingdom-based Legal & General Group Inc Pcl has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Manufacturers Life The holds 13,095 shares or 0% of its portfolio. Victory Cap Mgmt holds 0% or 282 shares. Ubs Asset Mgmt Americas Inc accumulated 39,898 shares. Nj State Employees Deferred Compensation Plan owns 0.12% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 13,125 shares. Citigroup reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Pinnacle Associates Limited reported 0.66% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Blackrock stated it has 1.52M shares. Iguana Healthcare Ltd Liability Co accumulated 150,000 shares. Dimensional Fund Advsrs L P invested in 90,750 shares or 0% of the stock. Switzerland-based Gam Ag has invested 0.48% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). First Mercantile Tru Communication, a Tennessee-based fund reported 2,714 shares. Metropolitan Life Ins Communication Ny reported 0% stake.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics has $130.0 highest and $10 lowest target. $55.18’s average target is -29.19% below currents $77.93 stock price. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. Credit Suisse downgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, June 29. Credit Suisse has “Underperform” rating and $10 target. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, August 31 with “Sell” rating. On Tuesday, October 3 the stock rating was maintained by Northland Capital with “Buy”. The firm has “Neutral” rating by Credit Suisse given on Monday, March 20. The rating was maintained by Deutsche Bank on Wednesday, August 9 with “Buy”. Stifel Nicolaus maintained it with “Buy” rating and $6000 target in Monday, June 26 report. The firm has “Buy” rating by Jefferies given on Wednesday, August 9. The rating was maintained by Chardan Capital Markets on Monday, July 27 with “Sell”. The company was maintained on Thursday, February 25 by Stifel Nicolaus. On Monday, October 26 the stock rating was initiated by Lake Street with “Buy”.

The stock increased 0.95% or $0.73 during the last trading session, reaching $77.93. About 571,388 shares traded or 3.91% up from the average. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since January 23, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 earnings per share, down 39.53 % or $0.51 from last year’s $-1.29 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23 % EPS growth.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $2.04 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

More news for Esperion Therapeutics, Inc. (NASDAQ:ESPR) were recently published by: Valuewalk.com, which released: “Activist Investor Report for December 29, 2017 – Esperion Therapeutics Inc …” on January 02, 2018. Fool.com‘s article titled: “Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017” and published on January 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: